Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$77.93 USD

77.93
3,220,670

-0.68 (-0.87%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $77.93 0.00 (0.00%) 6:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 246)

Industry: Medical - Instruments

Zacks News

Zacks Equity Research

Edwards Lifesciences Presents Positive Partner 3 Trial Data

Edwards Lifesciences (EW) expects SAPIEN 3 to gain FDA approval for the low-risk indication in late-2019.

Zacks Equity Research

Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus

Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus

Tracey Ryniec headshot

NASH, Allergies and Beauty Stocks: Invest or Not?

There's a lot of innovation going on at the biopharmaceutical companies but which areas should investors be targeting?

Zacks Equity Research

Medtronic (MDT) Releases Encouraging Evalut TAVR Result

Medtronic's (MDT) clinical study data shows that the low-risk aortic stenosis patients have special characteristics as they tend to be younger and active compared with the higher-risk equivalents.

Zacks Equity Research

Edwards Lifesciences (EW) Looks Good: Stock Adds 6.2% in Session

Edwards Lifesciences (EW) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Zacks Equity Research

Company News For Mar 19, 2019

Companies in the news are: OSTK, FIS, WP, EW and DERM

Zacks Equity Research

Edwards Lifesciences Makes Investments in Heart Failure Space

The two transactions align with Edwards Lifesciences' (EW) goal of making the most innovative medical care available to patients of structural heart disease.

Zacks Equity Research

Edwards Lifesciences to Buy CASMED to Boost Critical Care Arm

The CASMED buyout is expected to strengthen Edwards Lifesciences' (EW) position in smart monitoring technologies and boost top-line contributions from the Critical Care arm.

Zacks Equity Research

Edwards Lifesciences (EW) Q4 Earnings In Line, Revenues Top

Edwards Lifesciences (EW) Q4 results benefit from growth in all the businesses.

Zacks Equity Research

Edwards Lifesciences (EW) Q4 Earnings Meet Estimates

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0.00% and 0.41%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Medical Products' Earnings Lineup for Jan 31: EW, BAX & More

Let's take a look at the factors that are likely to influence the earnings results of a few Medical Products bigwigs within the broader Medical space.

Zacks Equity Research

What's in Store for Edwards Lifesciences' (EW) Q4 Earnings?

Edwards Lifesciences (EW) expected to see consistent performance by Surgical Structural Heart and Critical Care segments in Q4.

Zacks Equity Research

Edwards Lifesciences (EW) Reports Next Week: Wall Street Expects Earnings Growth

Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Can Edwards Lifesciences (EW) Keep the Earnings Surprise Streak Alive?

Edwards Lifesciences (EW) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Will Walgreens (WBA) Q1 Earnings Gain From Overall Strength?

Several planned developments, early benefits from new pharmacy contracts as well as increased volumes are consistently driving growth within Walgreens Boots' (WBA) Retail Pharmacy USA division.

Zacks Equity Research

Edwards Lifesciences Advances in AI With Bay Labs Tie-Up

Through the tie-up, Edwards Lifesciences (EW) aims at improving detection of heart diseases and enhancing quality by using Bay Labs' ability to apply AI to cardiovascular imaging.

Zacks Equity Research

Edwards Lifesciences' Critical Care Arm Solid, THVT View Dull

Edwards Lifesciences (EW) sees strong Critical Care division sales. Management expects sluggish underlying THVT sales for 2018.

Zacks Equity Research

Edwards Lifesciences (EW) Up 5.6% Since Last Earnings Report: Can It Continue?

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Edwards Lifesciences' CE Mark for SAPIEN 3 Boosts THVT Arm

Latest CE Mark receipt is expected to fortify Edwards Lifesciences' (EW) position in Europe.

Zacks Equity Research

Edwards Lifesciences (EW) Stock Sinks As Market Gains: What You Should Know

Edwards Lifesciences (EW) closed the most recent trading day at $149.75, moving -1.99% from the previous trading session.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Boeing, Texas Instruments, General Dynamics, American International, TD Ameritrade and Edwards Lifesciences

The Zacks Analyst Blog Highlights: Boeing, Texas Instruments, General Dynamics, American International, TD Ameritrade and Edwards Lifesciences